Seres Therapeutics Inc (NASDAQ:MCRB)
| 25.26 BATS BZX Real-Time Price As of 1:10pm ET |  -0.43 / -1.67%Today’s Change | 2.52 Today|||52-Week Range 33.00 | +632.17% Year-to-Date |
Latest MCRB News | Press Releases
| Chardan downgrades Seres Therapeutics to Neutral Sep 18 / Seeking Alpha - Paid Partner Content | Seres Therapeutics receives FDA feedback for SER-109 marketing application Sep 11 / Seeking Alpha - Paid Partner Content |
| Cassava Sciences, Evogene leads the healthcare gainers' pack, Ayala Pharmaceuticals, Clovis Oncology amond major losers Sep 18 / Seeking Alpha - Paid Partner Content | Seres Therapeutics closing in on U.S. application for C. diff candidate SER-109 Sep 11 / Seeking Alpha - Paid Partner Content |
| Cassava Sciences, Evogene lead the healthcare gainers' pack, Ayala Pharmaceuticals, Clovis Oncology among major losers Sep 18 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 25.69 |
| Today’s open | 25.31 |
| Day’s range | 24.50 - 25.77 |
| Volume | 16,340 |
| Average volume (3 months) | 2,261,058 |
| Market cap | $2.2B |
Data as of 1:10pm ET, 09/21/2020
Growth & Valuation
| Earnings growth (last year) | +48.91% |
| Earnings growth (this year) | +12.63% |
| Earnings growth (next 5 years) | -4.75% |
| Revenue growth (last year) | +22.07% |
| P/E ratio | NM |
| Price/Sales | 5.66 |
| Price/Book | -- |
Competitors
| ---- | ||
| EDITEditas Medicine Inc | -1.82 | -5.38% |
| SRNESorrento Therapeutic... | -0.05 | -0.53% |
| XNCRXencor Inc | -3.64 | -8.46% |
Data as of 1:11pm ET, 09/21/2020
Financials
| Next reporting date | November 5, 2020 |
| EPS forecast (this quarter) | -$0.26 |
| Annual revenue (last year) | $34.5M |
| Annual profit (last year) | -$70.3M |
| Net profit margin | -203.68% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
